Findings

What do systematic reviews say?

2,447 questions · 2,590 findings · 266 reviews

No studies found 699 · 27%GRADE not reported 289 · 11.2%Very low 614 · 23.7%Low 605 · 23.4%Moderate 322 · 12.4%High 61 · 2.4%

Hepatotoxicity · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).

1 finding from 1 review

Adherence6 · HIV‐negative people at risk of TB infection1

Rifampicin probably leads to higher adherence6 compared with isoniazid (moderate certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).

1 finding from 1 review

Hepatotoxicity:13 Grade 3 and 4 toxicity · HIV‐negative people at risk of TB infection1

Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).

1 finding from 1 review

Adherence · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).

1 finding from 1 review

Hepatotoxicity · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).

1 finding from 1 review